ABCL Shares Outstanding
Total shares outstanding each quarter, showing dilution from issuance or reduction from buybacks.
Shares Outstanding
Latest: 307M (2026Q2)
| Period | Value |
|---|---|
| 2021Q1 | 271M |
| 2021Q2 | 279M |
| 2021Q3 | 282M |
| 2022Q1 | 285M |
| 2022Q2 | 285M |
| 2022Q3 | 286M |
| 2023Q1 | 288M |
| 2023Q2 | 289M |
| 2023Q3 | 289M |
| 2023Q4 | 290M |
| 2024Q1 | 293M |
| 2024Q2 | 294M |
| 2024Q3 | 295M |
| 2024Q4 | 295M |
| 2025Q1 | 298M |
| 2025Q2 | 299M |
| 2025Q3 | 299M |
| 2025Q4 | 299M |
| 2026Q1 | 303M |
| 2026Q2 | 307M |
* In some reporting periods, diluted weighted-average shares are used instead of period-end shares outstanding. Please verify individual figures against the company's SEC filings.
Other Indicators
Other ABCL Charts
More quarter-by-quarter fundamentals for AbCellera Biologics Inc.
1 / 8
Revenue
EPS
Free Cash Flow
FCF Margin
P/E Ratio
Cumulative FCF
Total Assets
Rule of 40
Healthcare Comparison
1 / 3
Shares Outstanding
Shares Outstanding
Shares Outstanding
Latest Shares Outstanding: 307M (2026Q2); +2.7% YoY; +2.4% CAGR (5.25y).
Across the 20 quarters from 2021Q1 to 2026Q2, Shares Outstanding ranged from 271M in 2021Q1 to 307M in 2026Q2.